Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results

S. Viviani, G. Bonadonna, A. Santoro, V. Bonfante, M. Zanini, L. Devizzi, F. Soncini, P. Valagussa

Research output: Contribution to journalArticle

Abstract

Purpose: To compare, in a prospective randomized trial, the efficacy of two different sequences of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in untreated advanced Hodgkin's disease. Patients and Methods: From June 1982 to September 1990, 427 consecutive previously untreated patients with pathologic stage IB, IIA bulky, IIB, III (A and B), and IV (A and 8) disease were prospectively randomized to receive two different sequences of MOPP and ABVD for a minimum of six cycles followed by radiotherapy (median dose, 30 Gy) to the nodal site(s) of pretreatment bulky disease. Of 415 assessable patients, 211 received one cycle of MOPP monthly, alternated with one cycle of ABVD (alternating regimen), and 204 patients received one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period (hybrid regimen). Results: The complete remission (CR) rate was 91% with the alternating regimen and 89% with the hybrid regimen. At 10 years, the freedom-from-progression (FFP) rate was 67% versus 69% and the overall survival (OS) rate was 74% versus 72%, respectively. After attainment of CR, 85 patients relapsed in nodal (n = 60) versus extranodal with or without nodal (n = 25) sites. In patients given consolidative radiation because of bulky lymphoma, the true recurrence rate was 13%. A total of 23 second malignancies (6%) were documented, including 11 cases of acute nonlymphocytic leukemia. No cases of congestive heart failure attributable to doxorubicin or pulmonary toxicity related to bleomycin were documented. Conclusion: By delivering MOPP and ABVD, it is possible to cure approximately 70% of patients with advanced Hodgkin's disease. The two different drug sequences yielded superimposable results.

Original languageEnglish
Pages (from-to)1421-1430
Number of pages10
JournalJournal of Clinical Oncology
Volume14
Issue number5
Publication statusPublished - May 1996

Fingerprint

Procarbazine
Mechlorethamine
Dacarbazine
Vinblastine
Bleomycin
Vincristine
Prednisone
Hodgkin Disease
Doxorubicin
Second Primary Neoplasms
Acute Myeloid Leukemia
Lymphoma
Radiotherapy
Survival Rate
Heart Failure
Radiation
Recurrence
Drug Therapy
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease : Ten-year results. / Viviani, S.; Bonadonna, G.; Santoro, A.; Bonfante, V.; Zanini, M.; Devizzi, L.; Soncini, F.; Valagussa, P.

In: Journal of Clinical Oncology, Vol. 14, No. 5, 05.1996, p. 1421-1430.

Research output: Contribution to journalArticle

Viviani, S, Bonadonna, G, Santoro, A, Bonfante, V, Zanini, M, Devizzi, L, Soncini, F & Valagussa, P 1996, 'Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results', Journal of Clinical Oncology, vol. 14, no. 5, pp. 1421-1430.
Viviani, S. ; Bonadonna, G. ; Santoro, A. ; Bonfante, V. ; Zanini, M. ; Devizzi, L. ; Soncini, F. ; Valagussa, P. / Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease : Ten-year results. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 5. pp. 1421-1430.
@article{1e695e9cb42c4a55a9c5ead638cbd65e,
title = "Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results",
abstract = "Purpose: To compare, in a prospective randomized trial, the efficacy of two different sequences of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in untreated advanced Hodgkin's disease. Patients and Methods: From June 1982 to September 1990, 427 consecutive previously untreated patients with pathologic stage IB, IIA bulky, IIB, III (A and B), and IV (A and 8) disease were prospectively randomized to receive two different sequences of MOPP and ABVD for a minimum of six cycles followed by radiotherapy (median dose, 30 Gy) to the nodal site(s) of pretreatment bulky disease. Of 415 assessable patients, 211 received one cycle of MOPP monthly, alternated with one cycle of ABVD (alternating regimen), and 204 patients received one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period (hybrid regimen). Results: The complete remission (CR) rate was 91{\%} with the alternating regimen and 89{\%} with the hybrid regimen. At 10 years, the freedom-from-progression (FFP) rate was 67{\%} versus 69{\%} and the overall survival (OS) rate was 74{\%} versus 72{\%}, respectively. After attainment of CR, 85 patients relapsed in nodal (n = 60) versus extranodal with or without nodal (n = 25) sites. In patients given consolidative radiation because of bulky lymphoma, the true recurrence rate was 13{\%}. A total of 23 second malignancies (6{\%}) were documented, including 11 cases of acute nonlymphocytic leukemia. No cases of congestive heart failure attributable to doxorubicin or pulmonary toxicity related to bleomycin were documented. Conclusion: By delivering MOPP and ABVD, it is possible to cure approximately 70{\%} of patients with advanced Hodgkin's disease. The two different drug sequences yielded superimposable results.",
author = "S. Viviani and G. Bonadonna and A. Santoro and V. Bonfante and M. Zanini and L. Devizzi and F. Soncini and P. Valagussa",
year = "1996",
month = "5",
language = "English",
volume = "14",
pages = "1421--1430",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease

T2 - Ten-year results

AU - Viviani, S.

AU - Bonadonna, G.

AU - Santoro, A.

AU - Bonfante, V.

AU - Zanini, M.

AU - Devizzi, L.

AU - Soncini, F.

AU - Valagussa, P.

PY - 1996/5

Y1 - 1996/5

N2 - Purpose: To compare, in a prospective randomized trial, the efficacy of two different sequences of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in untreated advanced Hodgkin's disease. Patients and Methods: From June 1982 to September 1990, 427 consecutive previously untreated patients with pathologic stage IB, IIA bulky, IIB, III (A and B), and IV (A and 8) disease were prospectively randomized to receive two different sequences of MOPP and ABVD for a minimum of six cycles followed by radiotherapy (median dose, 30 Gy) to the nodal site(s) of pretreatment bulky disease. Of 415 assessable patients, 211 received one cycle of MOPP monthly, alternated with one cycle of ABVD (alternating regimen), and 204 patients received one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period (hybrid regimen). Results: The complete remission (CR) rate was 91% with the alternating regimen and 89% with the hybrid regimen. At 10 years, the freedom-from-progression (FFP) rate was 67% versus 69% and the overall survival (OS) rate was 74% versus 72%, respectively. After attainment of CR, 85 patients relapsed in nodal (n = 60) versus extranodal with or without nodal (n = 25) sites. In patients given consolidative radiation because of bulky lymphoma, the true recurrence rate was 13%. A total of 23 second malignancies (6%) were documented, including 11 cases of acute nonlymphocytic leukemia. No cases of congestive heart failure attributable to doxorubicin or pulmonary toxicity related to bleomycin were documented. Conclusion: By delivering MOPP and ABVD, it is possible to cure approximately 70% of patients with advanced Hodgkin's disease. The two different drug sequences yielded superimposable results.

AB - Purpose: To compare, in a prospective randomized trial, the efficacy of two different sequences of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in untreated advanced Hodgkin's disease. Patients and Methods: From June 1982 to September 1990, 427 consecutive previously untreated patients with pathologic stage IB, IIA bulky, IIB, III (A and B), and IV (A and 8) disease were prospectively randomized to receive two different sequences of MOPP and ABVD for a minimum of six cycles followed by radiotherapy (median dose, 30 Gy) to the nodal site(s) of pretreatment bulky disease. Of 415 assessable patients, 211 received one cycle of MOPP monthly, alternated with one cycle of ABVD (alternating regimen), and 204 patients received one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period (hybrid regimen). Results: The complete remission (CR) rate was 91% with the alternating regimen and 89% with the hybrid regimen. At 10 years, the freedom-from-progression (FFP) rate was 67% versus 69% and the overall survival (OS) rate was 74% versus 72%, respectively. After attainment of CR, 85 patients relapsed in nodal (n = 60) versus extranodal with or without nodal (n = 25) sites. In patients given consolidative radiation because of bulky lymphoma, the true recurrence rate was 13%. A total of 23 second malignancies (6%) were documented, including 11 cases of acute nonlymphocytic leukemia. No cases of congestive heart failure attributable to doxorubicin or pulmonary toxicity related to bleomycin were documented. Conclusion: By delivering MOPP and ABVD, it is possible to cure approximately 70% of patients with advanced Hodgkin's disease. The two different drug sequences yielded superimposable results.

UR - http://www.scopus.com/inward/record.url?scp=0029920895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029920895&partnerID=8YFLogxK

M3 - Article

C2 - 8622055

AN - SCOPUS:0029920895

VL - 14

SP - 1421

EP - 1430

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -